Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Tiziano Barbui(University of Bergamo), Francesco Passamonti(University of Milan), Alessandra Carobbio(Ospedale Papa Giovanni XXIII), Maria Chiara Finazzi(Ospedale Papa Giovanni XXIII), Daniele Vanni(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Mannelli(University of Florence), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Arianna Masciulli(Ospedale Papa Giovanni XXIII), Ana Triguero(Hospital Clínic de Barcelona), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Arianna Ghirardi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Chiara Paoli(University of Genoa), Elisa Rumi(University of Pavia), Helna Pettersson(NU Hospital Group), Alberto Álvarez‐Larrán(Hospital Clínic de Barcelona), Barbara Mora(Casa Sollievo della Sofferenza), Chiara Maccari(Azienda Ospedaliero-Universitaria Careggi)
Cited by 66
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k